Clinical trials: Nonalcoholic Steatohepatitis
NAFLD, Web
Web-based Interventions on Nonalcoholic Fatty Liver Disease (NAFLD) in Obese Children
The web-based continuity of care intervention model to provide comprehensive nursing interventions for obese children with NAFLD, always tracking their performance status, enabling them to grasp the knowledge of healthy weight…
- Conditions
- NAFLD, Web, Childhood Obesity
- Trial name
- NCT05527938
- Testing
- web-based intervention
- Where
- China
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Shaoxing Maternity and Child Health Care Hospital
Non-alcoholic Fatty Liver Disease
Single Dose of PF-06835919 Escalation Study in Healthy Adult Subjects
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of a single dose of PF-06835919 in healthy adult subjects.
- Trial name
- NCT02974374
- Testing
- PF-06835919
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
NAFLD (Non-alcoholic Fatty Liver Disease), NASH (Nonalcoholic Steatohepatitis)
a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic Fatty Liver Disease（NAFLD）
This is a randomized, double-blind, multicenter, placebo-controlled, multiple-dose escalating clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity profile of B1344 in patients with…
- Trial name
- NCT07128797
- Testing
- B1344
- Where
- 5 sites in China
- Volunteers
- 32 people
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
Fatty Liver, Liver Fibrosis
Effects of Docosahexaenoic Acid (DHA) on Children With Nonalcoholic Fatty Liver Disease (NAFLD)
The purpose of this interventional study is to evaluate the efficacy and tolerability of docosahexaenoic acid (DHA) in children or adolescents with well-characterized and liver biopsy confirmed nonalcoholic fatty liver disease…
- Conditions
- Fatty Liver, Liver Fibrosis, Obesity, Metabolic Syndrome
- Trial name
- EDACN (NCT00885313)
- Testing
- DHA250, DHA500, Lifestyle intervention
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Obesity
Signature Diagnostic of Non-alcoholic Steatohepatitis (NASH) by Infrared Light Spectroscopy
Evaluation of the diagnostic performance of an algorithm developed to detect metabolic profiles specific of non-alcoholic steatohepatitis NASH and based on the reading of a blood sample's infrared spectra
- Trial name
- SIGNALS (NCT03978247)
- Testing
- NASHMIR
- Where
- Belgium
- Volunteers
- 382 people
- Sponsor
- Diafir
Atherosclerosis, Cardiovascular Risk Factor
Early Vascular Ageing in the YOUth
This is a single-center observational study on adolescents to determine predictors of the early steps of the formation of atherosclerosis and to quantify their influence on Intima-Media-Thickness of the carotid artery and the…
- Conditions
- Atherosclerosis, Cardiovascular Risk Factor, Cardiovascular Diseases, Cardiovascular Pathology
- Trial name
- EVA4YOU (NCT04598685)
- Where
- Austria
- Volunteers
- 1,517 people, healthy volunteers welcome
- Sponsor
- VASCage GmbH
Non-alcoholic Fatty Liver Disease, Insulin Resistance
Selenoprotein P and Non-alcoholic Fatty Liver Disease
The pathogenesis of nonalcoholic fatty liver disease has not been fully elucidated. The most widely supported theory implicates insulin resistance as the key mechanism leading to hepatic steatosis, and perhaps also to…
- Trial name
- NCT01257685
- Where
- South Korea
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Korea University
NASH - Nonalcoholic Steatohepatitis
Estrogen Administration for the Treatment of NASH in Postmenopausal Women
Non-alcoholic fatty liver disease (NAFLD) is a growing epidemic in the United States. Despite this, the treatment options remain limited.
- Trial name
- NCT04833140
- Testing
- Estradiol patch
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Fat; Liver, NAFLD
The Effect of a High-fat vs. High-sugar Diet on Liver Fat Accumulation and Metabolism
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease in the world. It is currently unclear why fat starts to accumulate in the liver, although both the amount and type of food consumed have been…
- Trial name
- NCT03145350
- Testing
- High-fat, low-carbohydrate, Low-fat, high-carbohydrate
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Non-alcoholic Fatty Liver Disease, Obesity
A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease
This study is open to adults with overweight or obesity who also have fatty liver disease. The purpose of this study is to find the highest dose of BI 3006337 that people with overweight or obesity and with fatty liver disease…
- Trial name
- NCT05970640
- Testing
- BI 3006337
- Where
- 12 sites in United States
- Volunteers
- 64 people
- Sponsor
- Boehringer Ingelheim
Obesity, Diabetes Mellitus, Type 2
Bariatric Surgery-Induced Shift in Gut Microbiome and NAFLD
This study is designed as a prospective pilot study for longitudinal assessment of fecal microbiome related to medical and surgical weight loss.
- Conditions
- Obesity, Diabetes Mellitus, Type 2, NAFLD
- Trial name
- NCT04263376
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- The Cleveland Clinic
Non-Alcoholic Steatohepatitis
Safety and Tolerability of Yaq-001 in Patients With Non-Alcoholic Steatohepatitis
Gut-derived endotoxaemia, microbial imbalance and bacterial translocation play an increasingly recognized role in the progression from non-alcoholic fatty liver disease (NAFLD) to its more advanced state, NASH (non-alcoholic…
- Trial name
- NCT03962608
- Testing
- Yaq-001
- Where
- 9 sites in France, Italy and 4 more
- Sponsor
- Yaqrit Ltd
Obesity, Nonalcoholic Steatohepatitis
Controlled Trial of WLS vs. CLI for Severely Obese Adolescents With NASH
The goal of this study is to determine effective treatment and identify diagnostic biomarkers for Nonalcoholic steatohepatitis (NASH).
- Conditions
- Obesity, Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease
- Trial name
- NCT02412540
- Testing
- Comprehensive Lifestyle Intervention
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Nonalcoholic Steatohepatitis
Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)
The overall purpose of this study is to examine the safety, tolerability, pharmacokinetics (how the body processes a drug), and activity of GS-9450 in preventing liver damage due to scarring, or fibrosis, caused by Non-Alcoholic…
- Trial name
- NCT00740610
- Testing
- GS-9450
- Where
- 33 sites in United States, France
- Volunteers
- 124 people
- Sponsor
- Gilead Sciences
Vascular Stiffness, Liver Fibroses
Evaluation of the Effect of IHHT on Vascular Stiffness and Elasticity of the Liver Tissue in Patients With MS.
The aim of this study is to assess the effect of interval hypoxy-hyperoxic training (IHHT) on the arterial stiffness and elasticity of the liver tissue in patients with metabolic syndrome and on other components of the metabolic…
- Conditions
- Vascular Stiffness, Liver Fibroses, Metabolic Syndrome, Trimethylamine N-oxyde
- Trial name
- NCT04791397
- Testing
- Interval hypoxic-hyperoxic training (IHHT) using respiratory therapy unit ReOxy., Simulating Interval hypoxic-hyperoxic training (IHHT) using respiratory therapy unit ReOxy.
- Where
- Russia
- Volunteers
- 62 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Non Alcoholic Fatty Liver Disease
A Digital Solution for Individuals With Non Alcoholic Fatty Liver Disease
Sidekick Health has developed a digital behavioral change program (SK-241) specifically designed for people with metabolic derangements and non-alcoholic fatty liver disease (NAFLD).
- Trial name
- NCT05426382
- Testing
- A digital care solution for patients with NAFLD
- Where
- 2 sites in Iceland
- Volunteers
- 38 people
- Sponsor
- Sidekick Health
NAFLD, Heart Failure
T1-mapping by Cardiovascular Magnetic Resonance Imaging to Assess Non-Alcoholic Fatty Liver Disease
On clinically indicated Cardiovascular Magnetic Resonance studies, native T1-times and extracellular volume of the liver will be assessed and findings correlated with established risk calculators for non-alcoholic fatty liver…
- Conditions
- NAFLD, Heart Failure, Valvular Disease, Coronary Disease
- Trial name
- NCT04220450
- Testing
- T1 mapping on Cardiovascular Magnetic Resonance Studies
- Where
- Austria
- Volunteers
- 800 people
- Sponsor
- Dr. Andreas Kammerlander
Non-Alcoholic Fatty Liver Disease
Calisthenics Versus High Intensity Interval Training in NAFL
According to sample size calculation and after achieving the inclusion criteria, sixty patients with non-alcoholic fatty liver (NAFL) of both genders will be enrolled in this study and their ages will be ranged from30s-40s; they…
- Trial name
- NCT06032650
- Testing
- Calisthenics exercise and High intensity interval training
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Cairo University
MAFLD, Cholecystitis
Metabolic Dysfunction-Associated Fatty Liver Disease Impairs Intraoperative Indocyanine Green Fluorescence Cholangiography Quality: Development and Validation of a Predictive Model
Near-infrared fluorescence cholangiography has been shown to improve the clinical outcomes of laparoscopic cholecystectomy (LC).
- Conditions
- MAFLD, Cholecystitis, Gallbladder Polyps, Cholelithiasis
- Trial name
- NCT07297225
- Testing
- Retrospective observational study without intervention measures
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Zhujiang Hospital
Chronic Hepatitis b, NAFLD
Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients
Chronic hepatitis B (CHB) affects 257million individuals worldwide. In 2017, it caused around 39.7 million cases of cirrhosis and 0.4 million cirrhosis-related deaths in 2017.
- Conditions
- Chronic Hepatitis b, NAFLD, Cirrhosis, Fibrosis, Liver
- Trial name
- NCT05147090
- Testing
- Empagliflozin 10 MG
- Where
- Hong Kong
- Volunteers
- 106 people
- Sponsor
- The University of Hong Kong
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.